Clinical Trial

DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of adverse events. It will also measure the levels of DZD8586 in the body when combined with immunochemotherapy regimens.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-10; most recent amendment 2026-03-30.
Status change: Not Yet Recruiting → Recruiting 2025-08-22
Trial Details
NCT Number NCT07059650
Lead Sponsor Dizal Pharmaceuticals
Conditions Diffuse Large B-Cell Lymphoma
Enrollment 150 participants
Start Date 2025-08-19
Primary Completion 2030-10 (estimated)
Study Completion 2030-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-01